The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

J Salih, J Hilpert, T Placke, F Grünebach… - … Journal of cancer, 2010 - Wiley Online Library
In chronic myeloid leukemia (CML), BCR/ABL‐mediated oncogenic signaling can be
targeted with the BCR/ABL‐inhibitors Imatinib, Nilotinib and Dasatinib. However, these …
被引用次数：106 相关文章

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

J Salih, J Hilpert, T Placke… - … journal of cancer, 2010 - pubmed.ncbi.nlm.nih.gov
In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be
targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib. However, these …

[引用][C] The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity

J SALIH, J HILPERT, T PLACKE… - … journal of cancer …, 2010 - pascal-francis.inist.fr
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …

[引用][C] The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

J Salih, J Hilpert, T Placke, F Grünebach… - International Journal of …, 2010 - cir.nii.ac.jp

The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

J Salih, J Hilpert, T Placke, F Grünebach… - International Journal of …, 2010 - infona.pl
In chronic myeloid leukemia (CML), BCR/ABL‐mediated oncogenic signaling can be
targeted with the BCR/ABL‐inhibitors Imatinib, Nilotinib and Dasatinib. However, these …

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

J Salih, J Hilpert, T Placke, F Grünebach… - … Journal of Cancer, 2010 - europepmc.org
In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be
targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib. However, these …

[引用][C] Th e BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

J SALIH - Int J Cancer, 2010 - cir.nii.ac.jp
Th e BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell
reactivity | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

[引用][C] The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity

J SALIH, J HILPERT, T PLACKE… - … journal of cancer, 2010 - Wiley-Blackwell